Search results
Dr. Martin Hutchings received his medical degree and his PhD at the University of Copenhagen, Denmark. He is a staff specialist, Department of Hematology, at the Finsen Centre, National Hospital, Copenhagen University Hospital in Denmark. Dr. Hutchings is chairman of the Scientific Steering Committee for the EORTC Lymphoma Group and principal ...
- Newsletters
Join Dr. Shanbhag as he discusses the challenges in...
- Contact Us
Diffuse Large B-cell Lymphoma; Follicular Lymphoma; CLL in...
- Follicular Lymphoma
Spotlight on Relapsed/Refractory Follicular Lymphoma CME,...
- About Us
Managing Lymphoma is an educational online community for...
- Newsletters
Dec 8, 2023 · Correspondence Martin Hutchings, Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, Copenhagen 2100, Denmark; e-mail: Martin.Hutchings@regionh.dk.
Martin Hutchings 7500 Background: Glofitamab is a T-cell engaging bispecific antibody (Ab) with a novel 2:1 configuration that confers bivalency for CD20 (B cells) and monovalency for CD3 (T cells).
Rigshospitalet - Cited by 13,977
Martin Hutchings,1 Carmelo Carlo-Stella,2 Franck Morschhauser,3 Lorenzo Falchi,4 Emmanuel Bachy, 5 Guillaume Cartron, 6 Cyrus Khan, 7 Monica Tani, 8 Joaquin Martinez-Lopez, 9 Nancy L. Bartlett, 10 Antonio Salar, 11 Joshua Brody, 12 Sirpa Leppä, 13 Pauline Baumlin, 14 Estefania Mulvihill, 14
About Martin Hutchings. Martin, whose practice encompasses all aspects of banking work, advises borrowers and lenders on complex multijurisdictional transactions, with an emphasis predominantly on corporate treasury transactions, including acquisition finance, IPO facilities, liquidity facilities and general corporate financings.
Martin Hutchings, MD, PhD, of Copenhagen University Hospital, discusses a 5-year update of the phase III ECHELON-1 study, which suggested brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine benefits patients with previously untreated stage III or IV classical Hodgkin lymphoma (Abstract S205).
